Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.58 |
| ▸ | CTSS | P25774 | 10/20 | 0.58 |
| ▸ | CTSB | P07858 | 10/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207942 | 1.00 | CTSK (0.58) | CTSKCTSSCTSBCTSLGPR119 | |
| SCHEMBL4698976 | 0.97 | CTSK (0.56) | CTSKCTSSCTSBCTSLGPR119 | |
| SCHEMBL4698794 | 0.93 | CTSK (0.53) | CTSKCTSSCTSBGPR119PTPN2 | |
| SCHEMBL4701682 | 0.90 | CTSK (0.50) | CTSKCTSSCTSBGPR119 | |
| SCHEMBL4702138 | 0.89 | CTSK (0.51) | CTSKCTSSCTSBGPR119PTPN2 | |
| SCHEMBL4699551 | 0.87 | CTSK (0.49) | CTSKCTSSCTSBGPR119 | |
| SCHEMBL4701984 | 0.85 | CTSK (0.49) | CTSKCTSSCTSBGPR119 | |
| SCHEMBL4701983 | 0.85 | CTSK (0.49) | CTSKCTSSCTSBGPR119 | |
| SCHEMBL4700521 | 0.85 | CTSK (0.49) | CTSKCTSSCTSBGPR119TGFBR1 | |
| SCHEMBL4700127 | 0.84 | CTSK (0.54) | CTSKCTSSCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1372655-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-10-12 | — | — | EP | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
| EP-1372655-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002069901-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSK 4/4885CTSS 2/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.